In This Article:
It's been a good week for TG Therapeutics, Inc. (NASDAQ:TGTX) shareholders, because the company has just released its latest third-quarter results, and the shares gained 8.1% to US$27.17. Results overall were not great, with earnings of US$0.02 per share falling drastically short of analyst expectations. Meanwhile revenues hit US$84m and were slightly better than forecasts. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
See our latest analysis for TG Therapeutics
After the latest results, the nine analysts covering TG Therapeutics are now predicting revenues of US$540.9m in 2025. If met, this would reflect a sizeable 104% improvement in revenue compared to the last 12 months. Earnings are expected to improve, with TG Therapeutics forecast to report a statutory profit of US$1.01 per share. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$506.0m and earnings per share (EPS) of US$0.87 in 2025. So it seems there's been a definite increase in optimism about TG Therapeutics' future following the latest results, with a solid gain to the earnings per share forecasts in particular.
Althoughthe analysts have upgraded their earnings estimates, there was no change to the consensus price target of US$37.22, suggesting that the forecast performance does not have a long term impact on the company's valuation. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on TG Therapeutics, with the most bullish analyst valuing it at US$55.00 and the most bearish at US$9.00 per share. With such a wide range in price targets, analysts are almost certainly betting on widely divergent outcomes in the underlying business. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the TG Therapeutics' past performance and to peers in the same industry. We can infer from the latest estimates that forecasts expect a continuation of TG Therapeutics'historical trends, as the 77% annualised revenue growth to the end of 2025 is roughly in line with the 86% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 21% annually. So although TG Therapeutics is expected to maintain its revenue growth rate, it's definitely expected to grow faster than the wider industry.